Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05917145 · ClinicalTrials.gov registry record · Phase 1
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
A Phase 1 study of Glioblastoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT05917145 is a Phase 1 study of Glioblastoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 94 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05917145, a Phase 1 study of Glioblastoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Conditions Studied
Interventions
- DRUG WSD0628
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05917145
The ClinicalTrials.gov registry entry for NCT05917145 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (13% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which WSD0628 is the first listed.
NCT05917145 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05917145 about?
NCT05917145 is a clinical study titled "ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma". The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
What is the current status of trial NCT05917145?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2024-01-17. Estimated completion is 2029-02.
What conditions does trial NCT05917145 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05917145?
The interventions under investigation include: WSD0628 (DRUG).
Who is sponsoring clinical trial NCT05917145?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05917145 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.